tbuckley/cabot-search huggingface dataset:
Highlights in Head and Neck Cancer
Authors: Nicole G. Chau, Roy B. Tishler, Robert I. Haddad
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Clinical Characteristics and GVL Effect of Chronic Graft-Versus-Host disease Following Reduced-Intensity Umbilical Cord Blood Transplantation (RICBT).
Authors: Atsushi Wake, Naoyuki Uchida, Kazuya Ishiwata, Hideki Araoka, Masanori Tsuji, Nobuaki Nakano, Hisashi Yamamoto, Shinsuke Takagi, Daisuke Kato, Naofumi Matsuno, Sachiko Seo, Yuki Asano-Mori, Kazuhiro Masuoka, Shigeyoshi Makino, Akiko Yoneyama, Shuichi Taniguchi
Journal: Blood (2009)
Bioluminescent Imaging of Human Leukemic Stem Cell Engraftment.
Authors: Catriona Jamieson, Mobin Karimi, Remi Creusot, Robert Negrin, Jason Gotlib, Mark Chao, Carol Jones, Armand Keating, C. Garrison Fathman, James Zehnder, Irving L. Weissman
Journal: Blood (2005)
Clinical Characteristics and Treatment Allocations in Patients with Myelodysplastic Syndromes and Monosomy 7: Results from an International Multicenter Study Suggest That Hypomethylating Agents Significantly Improve Overall- and AML-Free Survival in Patients Classified As Very High Risk By IPSS-R
Authors: Julie Schanz, Friederike Braulke, Ghulam J. Mufti, Elena Crisà, Austin Kulasekararaj, Kathrin Nachtkamp, Ulrich Germing, Stefan Schmitz, Peter Haas, Michael Lübbert, Catharina Müller-Thomas, Katharina Götze, Uwe Platzbecker, Florian Nolte, Wolf-Karsten Hofmann, Detlef Haase
Journal: Blood (2014)
SP0085 Design of A Self-Management Intervention for Men with RA
Authors: C.A. Flurey
Journal: Annals of the Rheumatic Diseases (2016)

Rheumatoid arthritis affects more women than men (30% male) and current research reflects this difference. Evidence from several long term conditions suggests disease impacts differently on men compared to women, leading to the proposal that men need their own health strategy (White et al 2011). However, the coping styles and support needs of men with RA has not previously been the focus of discussion within rheumatology. If men experience and cope with RA differently to women then the support required is likely to be different. However, current self-management interventions in RA have been designed and tested mainly in women. This talk will address the experiences and coping styles of men with RA and their preferences for the design and delivery style of a self-management intervention. This talk will discuss the potential designs for a self-management intervention and potential solutions for engaging men in taking part in such an intervention. <h3>Disclosure of Interest</h3> C. Flurey Grant/research support from: Arthritis Research UK
Sqstm1 Is Required to Retain Hematopoietic Stem Cell/ Progenitors As a Negative Regulator of Macrophage-Dependent Inflammatory Signaling in the Bone Marrow Osteoblastic Niche
Authors: Kyung-Hee Chang, Amitava Sengupta, Ramesh C Nayak, Angeles Duran, Sang Jun Lee, Ronald Pratt, Ashley Wellendorf, Sarah Hill, Marcus Watkins, Roberto Civitelli, Daniel T Starczynowski, Maria T Diaz-Meco, Jorge Moscat, Jose A Cancelas
Journal: Blood (2014)
Long Lasting Alteration of Natural Killer Cells Post-Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML).
Authors: Daniel Olive, Nicolas Anfossi, Pascale Andre, Jerome Rey, Florence Orlanducci, Violette Breso, Valentine Peri, Thomas Prébet, Aude Charbonnier, Eloise Perrot, Francois Romagne, Norbert Vey
Journal: Blood (2009)
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents
Authors: Antoine Azan, Peter J. Caspers, Tom C. Bakker Schut, Séverine Roy, Céline Boutros, Christine Mateus, Emilie Routier, Benjamin Besse, David Planchard, Atmane Seck, Nyam Kamsu Kom, Gorana Tomasic, Senada Koljenović, Vincent Noordhoek Hegt, Matthieu Texier, Emilie Lanoy, Alexander M.M. Eggermont, Angelo Paci, Caroline Robert, Gerwin J. Puppels, Lluis M. Mir
Journal: Cancer Research (2016)

Raman spectroscopy is a noninvasive and label-free optical technique that provides detailed information about the molecular composition of a sample. In this study, we evaluated the potential of Raman spectroscopy to predict skin toxicity due to tyrosine kinase inhibitors treatment. We acquired Raman spectra of skin of patients undergoing treatment with MEK, EGFR, or BRAF inhibitors, which are known to induce severe skin toxicity; for this pilot study, three patients were included for each inhibitor. Our algorithm, based on partial least squares-discriminant analysis (PLS-DA) and cross-validation by bootstrapping, discriminated to variable degrees spectra from patient suffering and not suffering cutaneous adverse events. For MEK and EGFR inhibitors, discriminative power was more than 90% in the viable epidermis skin layer; whereas for BRAF inhibitors, discriminative power was 71%. There was a 81.5% correlation between blood drug concentration and Raman signature of skin in the case of EGFR inhibitors and viable epidermis skin layer. Our results demonstrate the power of Raman spectroscopy to detect apparition of skin toxicity in patients treated with tyrosine kinase inhibitors at levels not detectable via dermatological inspection and histological evaluation. Cancer Res; 77(2); 557-65. ©2016 AACR.
Loss of AKAP150 promotes pathological remodelling and heart failure propensity by disrupting calcium cycling and contractile reserve
Authors: Lei Li, Jing Li, Benjamin M. Drum, Yi Chen, Haifeng Yin, Xiaoyun Guo, Stephen W. Luckey, Merle L. Gilbert, G. Stanley McKnight, John D. Scott, L. Fernando Santana, Qinghang Liu
Journal: Cardiovascular Research (2016)

Impaired Ca2 + cycling and myocyte contractility are a hallmark of heart failure triggered by pathological stress such as hemodynamic overload. The A-Kinase anchoring protein AKAP150 has been shown to coordinate key aspects of adrenergic regulation of Ca2+ cycling and excitation–contraction in cardiomyocytes. However, the role of the AKAP150 signalling complexes in the pathogenesis of heart failure has not been investigated. Here we examined how AKAP150 signalling complexes impact Ca2+ cycling, myocyte contractility, and heart failure susceptibility following pathological stress. We detected a significant reduction of AKAP150 expression in the failing mouse heart induced by pressure overload. Importantly, cardiac-specific AKAP150 knockout mice were predisposed to develop dilated cardiomyopathy with severe cardiac dysfunction and fibrosis after pressure overload. Loss of AKAP150 also promoted pathological remodelling and heart failure progression following myocardial infarction. However, ablation of AKAP150 did not affect calcineurin-nuclear factor of activated T cells signalling in cardiomyocytes or pressure overload- or agonist-induced cardiac hypertrophy. Immunoprecipitation studies showed that AKAP150 was associated with SERCA2, phospholamban, and ryanodine receptor-2, providing a targeted control of sarcoplasmic reticulum Ca2+ regulatory proteins. Mechanistically, loss of AKAP150 led to impaired Ca2+ cycling and reduced myocyte contractility reserve following adrenergic stimulation or pressure overload. These findings define a critical role for AKAP150 in regulating Ca2+ cycling and myocardial ionotropy following pathological stress, suggesting the AKAP150 signalling pathway may serve as a novel therapeutic target for heart failure.
AB0327 An Audit of The Use of Biologic Therapies and Dosage Tapering in Stable Inflammatory Arthritis Patients: A Real Life Look at A District General Hospital's Patients
Authors: R. Rabbitts
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatology department at a South West England District General Hospital. <h3>Objectives</h3> To audit our use of biologic therapies in patients with inflammatory arthritis. To establish how many patients we are increasing the dosage interval, which patients we are choosing to do this for and what are the success rates from this. Evaluate what the financial implications are in doing this. <h3>Methods</h3> Using the "Homecare Patient List" patients with any inflammatory arthritis who were on a biologic medication were identified. Patients with a firm diagnosis of Rheumatoid Arthritis (RA) or Psoriatic Arthritis (PsA) were identified from this. Patients on one of 6 biologic medications (abatercept, adalimumab, certolizumab, etanercept, golimumab, and tocilizumab) were then included. Further inclusion criteria for the audit included being on a biologic medication for over 6 months (ie. Started before April 2015) and having regular follow up with our service (at least every 6 months). 148 patients were identified as suitable (108 Rheumatoid arthritis, 40 Psoriatic arthritis). Demographics were collected from hospital electronic records and then information regarding biologic medications and clinical status was taken from clinic letters using Epro records. Clinic letters prior to 2013 were not viewed. Results were collected in MS Excel template. <h3>Results</h3> Of the 108 RA patients; 76 female and 36 male, mean age was 61 years with a range of 32 years to 78 years. In 40 of these patients we attempted to taper the interval of their biologic medication. 87% of these patients were on methotrexate as an anchor medication. Biologic medications that were tapered included adalimumab, etanercept and certolizumab. In the 40 patients tapered this change has been maintained or increased in 28 patients, giving a success rate of 70%. 12 patients have returned to the original dosing regimen due to increased disease activity. In the Psoriatic Arthritis patient group, there were 21 females, 19 males, with a mean age of 52 years (age range 31 years to 73 years). In 5 of these patients we have attempted to taper the interval of their medication. The majority of those tapered were on monotherapy adalimumab. The changes were maintained in 80% of patients. <h3>Conclusions</h3> In total we have attempted to taper 30% of RA and PsA patients on biologic therapies, 71% of these attempts have been maintained or increased. We are increasing the dosage intervals successfully by varying amounts, with a range from 16% to 55%, and by a mean of 30.58% over all medications included. Etanercept has successfully had the largest increase in interval with dosing intervals increasing by a mean of 55% compared to once every 7 day dosing. This has significant financial implications with an annual savings of £72,108.60 based on the data in this audit. <h3>Disclosure of Interest</h3> None declared
OP0021-HPR Sleep Disorders in Patients with Rheumatoid Arthritis and Relationship with Disease Activity
Authors: L. Villarreal, J. Bello, P. Santos-Moreno, N. Palacio, C. Castro, D. Buitrago-Garcia
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The rheumatoid arthritis (RA), as known, causes inability in various performance areas mostly in the musculoskeletal. Reduced physical activity, substantial disability and also sleep disorders have previously been described in people with RA. <h3>Objectives</h3> The aim of this study was to describe the socio-demographic profile and sleep disorders in RA patients from a specialized RA clinic in Colombia. <h3>Methods</h3> A descriptive cross-sectional study was performed in a specialized clinic dedicated to care patients with rheumatoid arthritis (RA). 1298 patients were included in the study, which were seen by the area of psychology, which information was collected through semi-structured interviews and non-probability sampling. Descriptive epidemiology was applied for continuous variables, using measures of central tendency and dispersion for categorical and qualitative variables by averages and percentages. We used chi2 test to study a possible relationship between the severity of disease activity and the sleep disorders. <h3>Results</h3> Total sample of patients was 1298, 1048 (80%) were women and 250 (19%) were men. Patients had a DAS28 2.6 in average ± 1.1; mean age was 55.1 ± 8.8 years; 846 (65%) were in remission, 205 (16%) were in low disease activity, 208 (16%) in moderate disease activity and 42 in severe disease activity (3%). Regarding education, 6% were illiterate, 44% had elementary school, 33% high school, 8% had a technical degree and only 7% had college level. 373 (28%) patients showed any sleep disorder, among type of sleep disorders were seen: primary insomnia 299 patients (80% of women and 20% of men), related sleep disorder breathing (OSAS) 33 Patients (70% of women and 30% of men) and 20 patients with circadian rhythm disorder (74% of women and 26% of men), and hypersomnia 13 patients (92% of women and 8% men). It was established a relationship between having a sleep disorder and severity of disease activity statistically significant (p&lt;0.00). <h3>Conclusions</h3> According to these findings sleep disorders are likely present in a great proportion patients with RA and in many cases linked with disease activity. Primary insomnia is the most prevalent. <h3>Disclosure of Interest</h3> None declared
Severe Hemolysis Due to Passenger Lymphocyte Syndrome in Three Recipients of Organs from a Donor with Multiple Red Cell Alloantibodies.
Authors: Jake Shortt, Mark N. Polizzotto, David Roxby, Geoff Magrin, Andrew Webb, Marija Borosak, Glen Westall, Alison M. Street, Merrole F. Cole-Sinclair
Journal: Blood (2007)
Interruption of Bisphosphonates (BP) Therapy in Multiple Myeloma (MM) Patients and Osteonecrosis of the Jaw (ONJ).
Authors: Ashraf Badros, Olga Goloubeva, Dianna Weikel, Aaron P. Rapoport, Gorgun Akpek, Saul Yanovich, Timothy Meiller, Edward Sausville
Journal: Blood (2006)
Microtransplantation with Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes
Authors: Huisheng Ai, Kaixun Hu, Qiyun Sun, Xiao Li, Mei Guo, Changlin Yu, Jianhui Qiao, Junxiao Qiao, Guangxian Liu, Zheng Dong, Zhenhua Qiao
Journal: Blood (2012)
THU0361 Serum C5A Is Increased in Lupus Nephritis as Well as in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms
Authors: Y. Sakuma, T. Nagai, T. Yoshio, S. Hirohata
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown of blood brain barrier (BBB) plays a crucial role in the development of diffuse psychiatric/neuropsychological manifestations (diffuse NPSLE), allowing influx of neuron-reactive autoantibodies from systemic circulation into the brain (ref). Notably, C5a, a split product of C5, has been recently shown to cause BBB damages. Moreover, association of C5a with some forms of glomerulonephritis has been implicated. <h3>Objectives</h3> The present study therefore explored the levels of C5a in sera from patients with NPSLE and lupus nephritis (LN). <h3>Methods</h3> Serum specimens were obtained from 29 patients with NPSLE including 18 patients with diffuse NPSLE and 9 patients with neurologic syndromes (focal NPSLE), 25 patients with LN, 26 patients without NPSLE or LN (SLE alone), and from 21 healthy individuals. Cerebrospinal fluid (CSF) specimens were obtained from 29 patients with NPSLE on the same day of the collection of serum specimens. The levels of C5a, C5, C3 and C4 were measured by enzyme-linked immunosorbent assay. The BBB function was evaluated by CSF /serum albumin ratio (Q albumin). <h3>Results</h3> Serum C5a was significantly increased in 80 SLE patients compared with that in healthy individuals. Serum C5a was significantly elevated in NPSLE as well as in LN compared with that in SLE alone (figure), whereas there were no significant differences in serum C5 among these 3 groups. Serum C4, but not serum C3, was significantly lower in LN than that in NPSLE (figure), indicating the activation of complement classical pathway in LN, but not in NPSLE. Q albumin was significantly elevated in diffuse NPSLE compared with that in focal NPSLE, whereas there were no significant differences in CSF C5a and in serum C5a between these 2 groups. Notably, Both CSF C5 and CSF C5a were significantly correlated with Q albumin, whereas serum C5a, but not serum C5, was inversely correlated with Q albumin in NPSLE patients. <h3>Conclusions</h3> These results have disclosed that serum C5a was elevated in NPSLE as well as in LN through different mechanisms. Moreover, the data indicate that CSF C5a and C5 were elevated in NPSLE due to BBB damages. Finally, it is suggested that C5a might be consumed during the process of BBB damages. <h3>References</h3> Hirohata S, Arinuma Y, Yanagida T, Yoshio T. Arthritis Res Ther 16:R77, 2014 <h3>Disclosure of Interest</h3> None declared
R-CHOP Versus R-FC Followed by Maintenance with Rituximab Versus Interferon-Alfa: Outcome of the First Randomized Trial for Elderly Patients with Mantle Cell Lymphoma
Authors: J.C. Kluin-Nelemans, E. Hoster, J. Walewski, S. Stilgenbauer, C. H. Geisler, C. Gisselbrecht, U. Vehling-Kaiser, J. K. Doorduijn, M. Trneny, B. Coiffier, R. Forstpointner, H. Tilly, L. Kanz, M. Szymczyk, O. Hermine, W. Klapper, W. Hiddemann, M. Unterhalt, M. H. Dreyling
Journal: Blood (2011)
SP0007 Imaging in Diagnosis: How To Do
Authors: M. Østergaard
Journal: Annals of the Rheumatic Diseases (2016)

This talk reviews the current knowledge on how to use imaging in clinical practice in the diagnostic process, when peripheral or axial inflammatory diseases, such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis or gout, are suspected. Conventional radiography, magnetic resonance imaging (MRI), ultrasonography, computed tomography (CT), dual-energy CT and optical imaging will be addressed, as will international recommendations and criteria published by European League of Rheumatology (EULAR), American College of Rheumatology (ACR), The Assessment of SpondyloArthritis international Society (ASAS). The main focus will be how to do in current clinical practice. However, the talk will also briefly address recent and upcoming advances, which are likely to improve our routine clinical practice with the coming few years. <h3>Disclosure of Interest</h3> None declared
AB0224 Role of Anti-RA33 as A Biomarker for Diagnosis in Colombian Patients with Rheumatoid Arthritis
Authors: M. Peña, F. Rondόn
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Accurate and early diagnosis of rheumatoid arthritis (RA) is vital for the timely implementation of a comprehensive treatment aimed at halting or slowing its progression (1). The sensitivity of existing biomarkers, rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) is low (2). It requires a new diagnostic biomarker with better performance in RA. <h3>Objectives</h3> To evaluate the diagnostic value of anti-RA33 (3) test in a simple of RA patientes and controls of Bogotá, Colombia, by measuring its sensitivity, specificity, positive and negative likehood ratio compared to RF and anti-CCP. Additionally, to asses the association between clinical and serological variables with the functional impairment degree in patients with RA. <h3>Methods</h3> A cross-sectional study in a sample of 80 RA patients and 20 controls without RA who attended to outpatient service in two hospitals of Bogotá from 2014 until 2015 was conducted by measuring their sociodemographic characteristics, arthritis activity degree by DAS-28 index, functional ability by HAQ-DI score and serological status for anti-RA33, RF and anti-CCP. A statistic analysis with proportions, summary and dispersion measures, contingency tables for measure of sensitivity, specificity, likehood ratios, ROC curves and multiple linear regression analysis was performed. <h3>Results</h3> Sensitivity score for anti-RA33, RF and anti-CCP was 15%, 85% and 93% respectively; while specificity was 100%, 90% and 85% respectively. The positive likelihood ratio was 8.5 for RF and 6.2 for anti-CCP. Finally, negative likelihood ratio was 0.87 for anti-RA33, 0.16 for RF and 0.08 for anti-CCP. The anti-RA33 seropositive patients were greater arthritis activity and functional disability as well as higher titers of RF and anti-CCP although these differences were not statistically significant. Finally, a moderately strong positive correlation was found between DAS-28 and HAQ-DI scores (R<sup>2</sup> =0.51). In the multiple linear regression model, DAS-28 index was the only predictor variable that explained the changes in the HAQ-DI functional ability score. <h3>Conclusions</h3> Findings suggest that anti-RA33 test does not seem to have any clinical utility for the diagnosis of RA in Colombian population. The importance of DAS-28 activity index as a score of association with functional disability in patients with RA was confirmed. <h3>References</h3> Torpy JM, Perazza GD, Golub RM. Rheumatoid Arthritis. JAMA 2011;305(17):1824. Chang PY, Yang CT, Cheng CH, Yu KH. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis. Int J Rheum Dis. 2015 May 4. Hassfeld W, Steiner G, Hartmuth K, Kolarz G, Scherak O, Graninger W, Thumb N, Smolen JS. Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum. 1989 Dec;32(12):1515–20 <h3>Disclosure of Interest</h3> None declared